The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying
Some bodyhackers have the resources to use them under doctor supervision and are advanced users that carefully source peptides from what they believe to be reputable providers
The honest limitation: the GLP-1 plus GIP tier starts around $349, so patients who need tirzepatide-class medication pay premium-tier pricing similar to brand alternatives discounted cash programs
Ensuring equitable access to these effective but high-cost medications, as well as supporting individuals so that they can stay on the therapy long-term, should be a priority for our clinicians and policymakers. The findings, which were presented at the American Heart Association Scientific Sessions and simultaneously published in JAMA Cardiology, underscore the need to increase equitable access to this new class of pharmaceuticals
0.89], respectively in females
A) all generic cos were very low on their GLP1 forecast before the launch - a few 10s of crores at best in the 1st year eg A top co in India had a 10cr first yr sales forecast and is set to do a multiplier of that On top of that fewer than expected cos have launched B) online sales which is the biggest area of growth on GLP1s (pharmacies / Telehealth) doesnt get captured and so is direct sales